Physician profile
Lawrence E Nichols
NPI 1902885460
$3,210.49
in general payments reported to CMS, 2019-2025
27 companies · $16.64 in 2025
The $16.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $13.42 · 2021: $311 · 2022: $572 · 2023: $926 · 2024: $1,006 · 2025: $16.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $668.84 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbvie INC. | $601.74 | 2021-2024 | |
| Novo Nordisk INC | $520.97 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $208.72 | 2022-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $167.63 | 2022-2024 | Trulicity, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.78 | 2022-2024 | Jardiance |
| Pfizer INC. | $147.76 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $108.39 | 2022-2024 | |
| Lundbeck LLC | $85.32 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $71.38 | 2022-2024 | |
| Astellas Pharma US INC | $50.09 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $47.34 | 2022-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $47.18 | 2023-2024 | Rexulti |
| Mylan Specialty L.P. | $37.67 | 2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $32.49 | 2024-2025 | Uzedy, Austedo Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.85 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $30.45 | 2022-2023 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $30.23 | 2022 | |
| Boston Scientific Corporation | $26.20 | 2024 | Watchman Access System |
| Esperion Therapeutics, INC. | $20.88 | 2024 | Nexletol |
| Vertex Pharmaceuticals Incorporated | $19.74 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.63 | 2023 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $17.02 | 2022 | |
| Merck Sharp & Dohme LLC | $16.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.88 | 2023 | |
| Exeltis, USA INC. | $14.90 | 2023 | Slynd |
| Sumitomo Pharma America, INC. | $12.51 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.